APYX - Apyx Medical Corp Stock Price, Fair Value and News

1.59USD+0.06 (+3.92%)Delayed as of 17 May 2024, 12:24 pm ET

Market Summary

USD1.59+0.06

Delayedas of 17 May 2024, 12:24 pm

3.92%

APYX Stock Price

View Fullscreen

APYX RSI Chart

APYX Valuation

Market Cap

53.0M

Price/Earnings (Trailing)

-2.32

Price/Sales (Trailing)

1.05

EV/EBITDA

-2.62

Price/Free Cashflow

-5.24

APYX Price/Sales (Trailing)

APYX Profitability

EBT Margin

-45.63%

Return on Equity

-111.47%

Return on Assets

-32.25%

Free Cashflow Yield

-19.09%

APYX Fundamentals

APYX Revenue

Revenue (TTM)

50.5M

Rev. Growth (Yr)

-15.63%

Rev. Growth (Qtr)

-30.13%

APYX Earnings

Earnings (TTM)

-22.8M

Earnings Growth (Yr)

-117.51%

Earnings Growth (Qtr)

21.14%

Breaking Down APYX Revenue

52 Week Range

1.537.97

(Low)(High)

Last 7 days

-7.2%

Last 30 days

10.8%

Last 90 days

-33.6%

Trailing 12 Months

-74.1%

How does APYX drawdown profile look like?

APYX Financial Health

Current Ratio

5.87

Debt/Equity

1.63

Debt/Cashflow

-0.29

APYX Investor Care

Shares Dilution (1Y)

0.13%

Diluted EPS (TTM)

-0.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	50.5M	0	0	0
2023	44.2M	47.4M	50.3M	52.3M
2022	52.4M	51.4M	48.7M	44.5M
2021	31.4M	38.3M	43.2M	48.5M
2020	27.6M	25.3M	24.6M	27.7M
2019	18.8M	21.8M	25.7M	28.2M
2018	12.0M	13.4M	14.4M	16.6M
2017	30.5M	23.5M	16.1M	10.2M
2016	31.2M	33.2M	35.4M	36.6M
2015	27.3M	27.7M	28.7M	29.5M
2014	8.0M	14.4M	20.8M	27.7M
2013	26.6M	25.2M	13.4M	1.6M
2012	26.0M	26.6M	27.0M	27.7M
2011	24.8M	25.7M	25.5M	25.4M
2010	0	26.0M	25.1M	24.2M
2009	0	0	0	27.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Apyx Medical Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 12, 2023	hill matthew c	bought	5,475	2.19	2,500	chief financial officer
Nov 14, 2023	goodwin charles d. ii	bought	78,500	1.57	50,000	chief executive officer
Jul 12, 2023	waldman lawrence	acquired	15,853	2.97	5,338	-
Jun 26, 2023	hornsby todd	acquired	26,550	1.77	15,000	executive vice president
Jun 26, 2023	hornsby todd	sold	-113,400	7.56	-15,000	executive vice president
Jun 06, 2023	geraghty michael	acquired	27,900	2.79	10,000	-
Aug 29, 2022	goodwin charles d. ii	bought	70,067	5.96319	11,750	chief executive officer
Jul 11, 2022	citronowicz moshe	acquired	76,200	2.54	30,000	sr. v.p. of operations

Which funds bought or sold APYX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-59,705	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-27,531	29,716	-%
May 15, 2024	AlTi Global, Inc.	sold off	-100	-33,274	-	-%
May 15, 2024	Caption Management, LLC	added	270	75,820	157,907	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-39.29	-224,965	103,520	-%
May 15, 2024	PURA VIDA INVESTMENTS, LLC	sold off	-100	-209,600	-	-%
May 15, 2024	RTW INVESTMENTS, LP	sold off	-100	-2,688,020	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-33,531	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-26.48	-6,699	4,135	-%
May 15, 2024	MARSHALL WACE, LLP	sold off	-100	-214,355	-	-%

Are Funds Buying or Selling APYX?

Are funds buying APYX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APYX

No. of Funds

Unveiling Apyx Medical Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 09, 2024	vizirgianakis stavros g.	5.04%	1,746,191	SC 13D/A
Apr 05, 2024	archon capital management llc	5.69%	1,972,460	SC 13D
Apr 01, 2024	vizirgianakis stavros g.	5.04%	1,746,191	SC 13D
Mar 25, 2024	hirschman orin	0%	0	SC 13G/A
Feb 14, 2024	divisadero street capital management, lp	0.0%	0	SC 13G/A
Feb 14, 2024	pura vida investments, llc	0.23%	80,000	SC 13G/A
Feb 14, 2024	rtw investments, lp	3.0%	1,025,963	SC 13G/A
Feb 13, 2024	archon capital management llc	9.96%	3,452,030	SC 13G/A
Feb 07, 2024	hirschman orin	5.9%	2,040,540	SC 13G/A
Feb 02, 2024	cowen financial products llc	-	0	SC 13G/A

Recent SEC filings of Apyx Medical Corp

View All Filings

Date Filed	Form Type	Document
May 09, 2024	SC 13D/A	13D - Major Acquisition
May 09, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
May 09, 2024	3	Insider Trading
May 09, 2024	10-Q	Quarterly Report
Apr 05, 2024	SC 13D	13D - Major Acquisition
Apr 01, 2024	SC 13D	13D - Major Acquisition
Mar 25, 2024	SC 13G/A	Major Ownership Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report

Peers (Alternatives to Apyx Medical Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.4B	40.3B	-3.99%	-3.65%	32.43	4.52	-2.84%	-3.08%
BDX	68.4B	19.7B	2.45%	-5.81%	51.31	3.47	4.82%	-17.56%
ALGN	20.6B	3.9B	-10.40%	-6.17%	44.52	5.25	5.72%	46.72%
BAX	17.9B	14.9B	-11.17%	-17.84%	6.76	1.2	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.5B	12.5B	4.37%	-2.87%	24.53	0.76	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.13	3.23	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-63	1.5	0.23%	91.03%
AXNX	3.5B	387.1M	0.46%	29.28%	-216.68	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.88	0.4	7.94%	-1661.78%
ANIK	378.1M	169.3M	-	-1.96%	-4.92	2.23	7.49%	-244.90%
ANGO	257.2M	324.0M	-1.38%	-32.77%	-1.34	0.79	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

Apyx Medical Corp News

Latest updates

Apyx Medical Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-30.1%	10,244,000	14,662,000	11,976,000	13,569,000	12,142,000	12,611,000	9,114,000	10,292,000	12,493,000	16,824,000	11,831,000	11,224,000	8,638,000	11,464,000	6,954,000	4,296,000	4,997,000	8,382,000	7,575,000	6,649,000	5,629,000
Gross Profit	-33.4%	5,949,000	8,929,000	7,978,000	9,279,000	7,573,000	8,241,000	5,757,000	6,914,000	8,219,000	12,151,000	8,056,000	7,534,000	5,860,000	7,701,000	4,725,000	2,094,000	2,984,000	5,563,000	5,294,000	4,674,000	3,563,000
Operating Expenses	-14.6%	12,564,000	14,705,000	12,615,000	13,206,000	13,184,000	14,174,000	11,539,000	12,890,000	14,090,000	13,843,000	12,024,000	11,577,000	10,605,000	9,754,000	9,096,000	8,261,000	10,476,000	11,524,000	10,050,000	9,096,000	9,293,000
S&GA Expenses	-27.2%	4,897,000	6,724,000	4,841,000	5,378,000	5,255,000	5,809,000	4,671,000	4,539,000	5,465,000	6,021,000	4,611,000	4,261,000	3,724,000	2,996,000	2,706,000	2,189,000	3,796,000	3,870,000	3,836,000	3,037,000	2,957,000
R&D Expenses	11.9%	1,397,000	1,248,000	1,276,000	1,199,000	1,121,000	1,255,000	1,061,000	1,070,000	1,158,000	947,000	1,175,000	1,084,000	1,115,000	918,000	1,047,000	975,000	980,000	1,097,000	1,016,000	888,000	730,000
EBITDA Margin	-7.3%	-0.37	-0.35	-0.31	-0.36	-0.49	-0.49	-0.37	-0.32	-0.29	-0.29	-0.32	-0.37	-	-	-	-	-	-	-	-	-
Interest Expenses	25.1%	1,396,000	1,116,000	585,000	543,000	234,000	3,000	1,000	3,000	8,000	1,000	3,000	2,000	4,000	7,000	25,000	8,000	6,000	8,000	-	-	-
Income Taxes	-39.1%	53,000	87,000	-318,000	66,000	-2,267,000	151,000	50,000	96,000	70,000	134,000	73,000	107,000	66,000	-391,000	-715,000	-1,492,000	-4,905,000	-383,000	171,000	76,000	6,000
Earnings Before Taxes	21.0%	-7,537,000	-9,537,000	-4,993,000	-953,000	-5,799,000	-5,914,000	-5,745,000	-5,354,000	-5,898,000	-1,876,000	-4,161,000	-3,944,000	-4,839,000	-1,922,000	-4,449,000	-6,182,000	-6,856,000	-5,816,000	-4,199,000	-4,219,000	-5,602,000
EBT Margin	-12.2%	-0.46	-0.41	-0.35	-0.39	-0.52	-0.51	-0.39	-0.34	-0.30	-0.31	-0.34	-0.40	-	-	-	-	-	-	-	-	-
Net Income	21.1%	-7,576,000	-9,607,000	-4,629,000	-994,000	-3,483,000	-6,049,000	-5,764,000	-5,426,000	-5,945,000	-2,003,000	-4,222,000	-4,046,000	-4,901,000	-1,527,000	-3,728,000	-4,690,000	-1,951,000	-5,433,000	-4,370,000	-4,295,000	-5,608,000
Net Income Margin	-26.5%	-0.45	-0.36	-0.30	-0.34	-0.47	-0.52	-0.39	-0.34	-0.31	-0.31	-0.34	-0.37	-	-	-	-	-	-	-	-	-
Free Cashflow	-182.6%	-6,376,000	-2,256,000	3,489,000	-4,975,000	-1,991,000	-4,672,000	-5,548,000	-6,273,000	-4,797,000	-118,000	-3,775,000	-5,035,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.8%	71.00	79.00	59.00	62.00	57.00	52.00	55.00	59.00	63.00	69.00	68.00	70.00	71.00	74.00	75.00	78.00	82.00	85.00	87.00	89.00	92.00
Current Assets	-12.0%	62.00	70.00	50.00	53.00	53.00	43.00	46.00	51.00	55.00	61.00	60.00	62.00	63.00	66.00	68.00	70.00	74.00	77.00	79.00	82.00	85.00
Cash Equivalents	-14.6%	37.00	44.00	22.00	19.00	16.00	10.00	15.00	20.00	26.00	31.00	31.00	35.00	40.00	42.00	44.00	46.00	51.00	59.00	62.00	67.00	32.00
Inventory	-1.3%	10.00	10.00	11.00	11.00	11.00	12.00	12.00	10.00	7.00	7.00	6.00	5.00	4.00	4.00	5.00	5.00	6.00	5.00	7.00	6.00	6.00
Net PPE	-7.1%	2.00	2.00	2.00	2.00	2.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	7.00	7.00	6.00	6.00	7.00	7.00	7.00	6.00	6.00
Liabilities	-4.0%	50.00	52.00	26.00	26.00	21.00	14.00	13.00	13.00	13.00	15.00	13.00	12.00	11.00	10.00	11.00	11.00	12.00	13.00	10.00	8.00	9.00
Current Liabilities	-17.1%	11.00	13.00	10.00	19.00	19.00	12.00	11.00	11.00	12.00	13.00	12.00	11.00	10.00	9.00	10.00	10.00	11.00	12.00	9.00	8.00	9.00
Long Term Debt	0.7%	33.00	33.00	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	9.00	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	33.00	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-23.4%	20.00	27.00	33.00	37.00	36.00	38.00	42.00	46.00	50.00	54.00	55.00	58.00	60.00	64.00	64.00	67.00	70.00	71.00	76.00	79.00	83.00
Retained Earnings	-13.9%	-62.02	-54.45	-44.84	-40.21	-39.22	-35.73	-29.69	-23.92	-18.50	-12.55	-10.55	-6.33	-2.28	3.00	4.00	8.00	13.00	15.00	20.00	24.00	29.00
Additional Paid-In Capital	1.4%	82.00	81.00	78.00	77.00	75.00	73.00	72.00	70.00	68.00	66.00	65.00	64.00	62.00	61.00	60.00	59.00	58.00	57.00	56.00	55.00	54.00
Accumulated Depreciation	3.4%	4.00	4.00	-	-	3.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00	-	-	-
Shares Outstanding	0.0%	35.00	35.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	34.00	34.00	34.00	-	-	-	-	-	-	-	-	-
Minority Interest	-6.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Float	-	-	-	-	168	-	-	-	202	-	-	-	354	-	-	-	190	-	-	-	227	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-193.2%	-6,341	-2,163	3,663	-4,819	-1,881	-4,530	-5,360	-5,872	-4,518	214	-3,605	-5,006	-2,052	-1,017	-2,616	-5,026	-7,407	-3,251	-4,549	-5,586	-5,089
Share Based Compensation	23.4%	1,128	914	1,351	1,482	1,367	1,641	1,692	1,714	1,650	1,341	1,184	1,369	1,194	1,001	1,063	1,097	1,049	987	543	856	1,195
Cashflow From Investing	62.4%	-35.00	-93.00	-174	7,111	-110	-142	-188	-401	-279	-332	-170	-29.00	-192	-388	-9.00	-94.00	-90.00	-225	-558	40,483	20,841
Cashflow From Financing	-100.0%	-5.00	23,844	164	46.00	8,112	-10.00	127	2.00	98.00	-39.00	-33.00	157	-61.00	-134	109	-63.00	15.00	-5.00	37.00	48.00	67.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APYX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Sales	$ 10,244	$ 12,142
Cost of sales	4,295	4,569
Gross profit	5,949	7,573
Other costs and expenses:
Research and development	1,397	1,271
Professional services	1,574	1,740
Salaries and related costs	4,696	4,918
Selling, general and administrative	4,897	5,255
Total other costs and expenses	12,564	13,184
Loss from operations	(6,615)	(5,611)
Interest income	495	51
Interest expense	(1,396)	(234)
Other loss, net	(21)	(5)
Total other loss, net	(922)	(188)
Loss before income taxes	(7,537)	(5,799)
Income tax expense (benefit)	53	(2,267)
Net loss	(7,590)	(3,532)
Net loss attributable to non-controlling interest	(14)	(49)
Net loss attributable to stockholders	$ (7,576)	$ (3,483)
Loss per share:
Basic (in dollars per share)	$ (0.22)	$ (0.10)
Diluted (in dollars per share)	$ (0.22)	$ (0.10)

APYX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 37,282	$ 43,652
Trade accounts receivable, net of allowance of $605 and $608	12,487	14,023
Inventories, net of provision for obsolescence of $880 and $875	9,795	9,923
Prepaid expenses and other current assets	2,362	2,764
Total current assets	61,926	70,362
Property and equipment, net of accumulated depreciation and amortization of $3,642 and $3,522	1,779	1,915
Operating lease right-of-use assets	5,049	5,162
Finance lease right-of-use assets	64	69
Other assets	1,893	1,732
Total assets	70,711	79,240
Current liabilities:
Accounts payable	2,103	2,712
Accrued expenses and other current liabilities	8,077	9,661
Current portion of operating lease liabilities	356	347
Current portion of finance lease liabilities	20	20
Total current liabilities	10,556	12,740
Long-term debt, net of debt discounts and issuance costs	33,406	33,185
Long-term operating lease liabilities	4,795	4,896
Long-term finance lease liabilities	48	53
Long-term contract liabilities	1,252	1,246
Other liabilities	194	198
Total liabilities	50,251	52,318
EQUITY
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,926 issued and outstanding as of March 31, 2024 and 34,643,888 issued and outstanding as of December 31, 2023	35	35
Additional paid-in capital	82,242	81,114
Accumulated deficit	(62,024)	(54,448)
Total stockholders' equity	20,253	26,701
Non-controlling interest	207	221
Total equity	20,460	26,922
Total liabilities and equity	$ 70,711	$ 79,240

About Apyx Medical Corp

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures. The company's Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also offers hand pieces for open and laparoscopic procedures, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

CEO	Mr. Charles D. Goodwin II
WEBSITE	apyxmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	276

Apyx Medical Corp Frequently Asked Questions

What is the ticker symbol for Apyx Medical Corp? What does APYX stand for in stocks?

APYX is the stock ticker symbol of Apyx Medical Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Apyx Medical Corp (APYX)?

As of Thu May 16 2024, market cap of Apyx Medical Corp is 53.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APYX stock?

You can check APYX's fair value in chart for subscribers.

What is the fair value of APYX stock?

You can check APYX's fair value in chart for subscribers. The fair value of Apyx Medical Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Apyx Medical Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Apyx Medical Corp a good stock to buy?

The fair value guage provides a quick view whether APYX is over valued or under valued. Whether Apyx Medical Corp is cheap or expensive depends on the assumptions which impact Apyx Medical Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APYX.

What is Apyx Medical Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, APYX's PE ratio (Price to Earnings) is -2.32 and Price to Sales (PS) ratio is 1.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APYX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Apyx Medical Corp's stock?

In the past 10 years, Apyx Medical Corp has provided -0.095 (multiply by 100 for percentage) rate of return.